CLINICAL TRIALS PROFILE FOR EGATEN

All Clinical Trials for EGATEN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04230148 ↗	Study of Safety, Tolerability and Clinical Outcomes of Egaten in Fascioliasis Patients (6 Years of Age or Older).	Not yet recruiting	Novartis Pharmaceuticals	Phase 4	2021-10-29	This is a multicenter, open label, non-comparative, single arm multi-country study in approximately 300 adult and pediatric subjects (≥ 6 years of age) with fascioliasis. The study population consists of male and female adult and pediatric patients (≥ 6 years of age). The study will enroll approximately 300 subjects with acute (minimum 15% of overall study population) or chronic fascioliasis. Enrolled subjects will receive two doses of 10 mg/kg of Egaten given approximately 12 hours apart. Subjects will be treated and followed up on an outpatient basis. After screening and post treatment, at Day 3 and Day 6 the subjects will be followed for safety and tolerability. These visits are primarily for safety follow up and may be telephonic or home visit by qualified personnel or onsite visits based on the investigator's discretion. During visits Day 10, Day 30, Day 60 and Day 90 post-treatment, the subjects will be followed for safety, tolerability and efficacy. On Day 15, Day 45 and Day 75, telephonic follow-up (primarily for safety) will be conducted.

Clinical Trial Conditions for EGATEN

Condition Name

Condition Name for EGATEN
Intervention	Trials
Fascioliasis	1

Condition MeSH

Condition MeSH for EGATEN
Intervention	Trials
Fascioliasis	1

Clinical Trial Progress for EGATEN

Clinical Trial Phase

Clinical Trial Phase for EGATEN
Clinical Trial Phase	Trials
Phase 4	1

Clinical Trial Status

Clinical Trial Status for EGATEN
Clinical Trial Phase	Trials
Not yet recruiting	1

Clinical Trial Sponsors for EGATEN

Sponsor Name

Sponsor Name for EGATEN
Sponsor	Trials
Novartis Pharmaceuticals	1

Sponsor Type

Sponsor Type for EGATEN
Sponsor	Trials
Industry	1

EGATEN Market Analysis and Financial Projection

Last updated: May 6, 2026

EGATEN (Drug) Clinical Trials Update, Market Analysis, and Projection

What is EGATEN and what indication is it in?

No reliable, citable public record is available in the provided context to identify EGATEN’s active ingredient, INN, sponsor, or the clinical indication(s) it targets. Without an unambiguous product identity (active moiety and indication), a clinical trials update and market projection cannot be produced without risking misattribution.

What is the current clinical-trials status for EGATEN?

No sufficient, citable source detail is available in the provided context to compile EGATEN’s:

• Phase (I/II/III), trial registration IDs, and enrollment status
• Primary endpoints and readout timelines
• Geographic footprint and dosing regimen
• Interim results or safety signals
• Comparative landscape versus current standard of care

How big is the EGATEN market and what drives it?

No reliable, citable product identity (active ingredient and indication) is available in the provided context. Market sizing depends on at least:

• Indication epidemiology (patient population)
• Treatment setting (first-line vs later-line; line of therapy)
• Comparator pricing and reimbursement structure
• Mechanism-of-action class and expected uptake dynamics

What revenue projection is supportable for EGATEN?

No indication or mechanism-linked commercial assumptions can be mapped to EGATEN without risking a false projection. A credible forecast requires:

• Country coverage and pricing basis
• Uptake curve assumptions tied to efficacy/safety and trial readouts
• Line-of-therapy adoption and competitive positioning
• Patent/market exclusivity and regulatory timing

What can be concluded now for investors and R&D planners?

Nothing can be concluded with actionable accuracy from the information provided.

---

Key Takeaways

• A clinical trials update, market analysis, and revenue projection for “EGATEN” cannot be generated without an unambiguous identification of the product (active ingredient/INN) and the indication(s) being developed.
• Any attempt to forecast timelines, trial status, or market size without that identity risks producing an incorrect basis for investment and R&D decisions.

---

FAQs

1. What does “EGATEN” refer to (active ingredient and indication)?
   It is not identifiable from the provided context in a way that supports reliable patent and clinical-trials analysis.

2. Where should clinical trials for EGATEN be checked?
   The standard approach is trial registry searches by exact drug name and sponsor, but no registry details are provided here.

3. How is market size projected for a biotech product like EGATEN?
   By indication patient pool, treatment penetration, expected uptake, pricing, and reimbursement, all of which require the drug’s active ingredient and indication.

4. Can a revenue forecast be produced without phase results?
   Not at investment-grade accuracy, because uptake assumptions depend on demonstrated efficacy and safety.

5. What inputs are essential to build an EGATEN projection model?
   Active ingredient (or INN), indication, trial phase and readout timing, comparator set, pricing/reimbursement targets, and launch geography.

---

References

[1] No citable sources were provided in the prompt context.